Stock DNL DIUL GROUP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

DIUL GROUP

Equities

DNL

GB00BDB6Q760

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about DIUL GROUP

Diurnal Ltd. Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023 CI
Diurnal Shares Delisted After Neurocrine Biosciences Takeover MT
Diurnal's Takeover Scheme By US-based Neurocrine Biosciences Becomes Effective MT
Neurocrine Biosciences, Inc. completed the acquisition of Diurnal Group plc from Diurnal Directors, IP Group Plc, Polar Capital Holdings plc, Development Bank of Wales Plc, Amati Global Investors Ltd. and other shareholders. CI
TRADING UPDATES: SulNOx, Marwyn loss widens; Kropz gets new facility AN
Neurocrine's Acquisition of Diurnal Secures Court Approval MT
TRADING UPDATES: Trackwise Designs wins deal; Cake Box names CFO AN
Diurnal's Shareholders Approve Takeover Bid by Neurocrine MT
UK shareholder meetings calendar - next 7 days AN
Diurnal Group Wins Recommendation for Rare Genetic Disorder Drug in Wales MT
Diurnal Group plc Announces AWMSG Recommends Efmody for CAH within NHS Wales CI
Diurnal Group plc Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Diurnal Group plc Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Denmark's Brain+ Hires Diurnal Chairman to Lead Board MT
FTSE Plunges 0.9% as Energy, Mining Stocks Slide DJ
Supermarkets Forecast to Relatively Outperform Retail Sector DJ
FTSE 100 Led Higher by Banks, Energy Stocks DJ
Sterling Struggles Continue as Gas Crisis, Structural Issues Weigh DJ
FTSE 100 Seen Opening Higher, Buoyed by Firmer U.S. Futures DJ
Diurnal Group Accepts $57 Million Takeover Offer From Neurocrine Biosciences MT
Diurnal Group plc announces First Patient Dosed in Pivotal Phase 3 Connect Clinical Trial for Us and Japanese Markets CI
Diurnal Group plc Announces Presentation At European Congress of Endocrinology CI
Diurnal Extends Swiss Distribution Deal With EffRx to Include Rare Disease Drug Efmody MT
Diurnal Group plc Extends Its Distribution and Marketing Agreement with Effrx Pharmaceuticals CI
Diurnal Grants Er-Kim Rights to Market Alkindi, Efmody in Greece, Cyprus, Malta MT

Chart DIUL GROUP

Chart DIUL GROUP
More charts

Company Profile

Diurnal Group plc is a specialty pharmaceutical company. It is focused on developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. It focuses on addressing unmet clinical and patient needs in hormone replacement by developing and marketing products for the rare and orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI). The Company's products include Alkindi and Efmody. Its product Alkindi (hydrocortisone granules in capsules for opening) is a specifically designed for young children suffering from paediatric AI, and the related condition CAH. Its product Efmody (modified-release hydrocortisone) provides a drug release profile that is designed to improve disease treatment for adults with CAH, as measured by androgen (male sex hormone) control. Its pipeline includes DNL-0200, DNL-0300, DNL-0400 and DNL-0500.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. DNL Stock
  4. News DIUL GROUP
  5. Diurnal's Takeover Scheme By US-based Neurocrine Biosciences Becomes Effective